ClinicalTrials.gg
CompletedNCT01895777Updated Jul 7, 2020Results posted

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

A Phase 3 interventional study of dabigatran etexilate and standard of care in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 65 sites in 26 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.

Enrollment
7th of 17
267 · median 148
Started
2013
with 2 others
Phase 3
6 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 7th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 3, and was the 10th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing dabigatran in Venous Thromboembolism, or all of them as a file.
02

Study summary

The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years of age.

03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 0 to less than 18 years of age at the time of / assent
  • Documented diagnosis of clinically stable VTE (e.g. DVT, PE, central line thrombosis, sinus vein thrombosis) per investigator judgment, initially treated (minimum of 5 to 7 days, but not longer than 21 days) with parenteral anticoagulation therapy, such as unfractionated heparin (UFH) or a low molecular weight heparin (LMWH).
  • Clinical indication for at least 3 month of treatment with anticoagulants for the VTE episode defined under the above inclusion criterion.
  • Written informed consent provided by the patient's parent or legal guardian and assent provided by the patient (if applicable) at the time of informed consent form (ICF) signature according to local regulations.

Exclusion criteria

Exclusion criteria:

  • Conditions associated with an increased risk of bleeding
  • Renal dysfunction ( \< 50 mL/min/1.73m\^2 using the Schwartz formula) or requirement for dialysis. eGFR retesting during the screening period is allowed (once).
  • Active infective endocarditis
  • Subjects with a heart valve prosthesis requiring anticoagulation.
  • Hepatic disease:

Active liver disease, including known active hepatitis A, B or C or, Persistent (ALT) or aspartate transaminase (AST) or alkaline phosphatase (AP) > 3 × (ULN) within 3 months of screening

  • Pregnant or breast feeding females. Females who have reached menarche and are not using a medically accepted method per local guidelines. Acceptable methods of birth control must be used in a correct and consistent manner
  • Patients in stratum 3 (0 to \< 2 years) with gestational age at birth \< 37 weeks or with body weight lower than the 3rd percentile
  • Anemia ( \< 80g/L) or thrombocytopenia ( count \< 80 x 109/L) at screening. Transfusions during the screening period are allowed, provided that a satisfactory hemoglobin or platelet level is attained prior to visit 2
  • Patients who have taken prohibited or restricted medication within one week of the first dose of study medication other than medication for prior VTE treatment and P-glycoprotein inhibitors..
  • Patients who have received an drug in the past 30 days prior to screening
  • Patients who are allergic/sensitive to any component of the study medication including solvent
  • Patients or parents/legal guardians considered unreliable to participate in the trial per investigator judgment or any condition which would present a safety hazard to the patient based on investigator judgment
  • Patients or parents/legal guardians who are unwilling or unable to undergo or permit repeat of the baseline imaging tests required to confirm thrombus resolution at study day 84 (or eEOT, whichever comes first) or in whom repeating such imaging tests at these pre-specified time points may not be medically in the patient's best interest. Examples may include unwarranted radiation exposure as a result of a repeat CT scan at day 84 for a patient with an isolated case of pulmonary embolism evaluated at baseline solely by a CT scan. In such cases, the baseline radiological assessment (e.g. CT) may be supplemented with an acceptable non-radiological assessment at baseline (e.g. MRI) which could then be repeated at day 84 hence alleviating any potential unwarranted radiation exposure.
  • Further exclusion criteria apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    dabigatran etexilate

    Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months

    Drug: dabigatran etexilate

  • Active comparator
    standard of care

    Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)

    Drug: standard of care

Interventions

  • Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation

  • Drugstandard of care

    Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)

06

What researchers measure

Primary outcomes

  1. Composite Primary Endpoint

    The primary endpoint was the combined endpoint of the proportions of patients with: * Complete thrombus resolution * Freedom from recurrent VTE * Freedom from mortality related to VTE. The events outlined in the above combined primary endpoint were assessed by radiologists or other such qualified clinicians using an appropriate method such as ultrasound, echocardiography, venography, or CT scan, based on the location of the thrombus and the test used to perform the baseline assessment. The primary efficacy endpoint contained 3 components. Each component was evaluated separately, and only if the criteria for all 3 components were satisfied, the primary endpoint was considered achieved.

    Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.

Secondary outcomes

  1. Freedom From Major Bleeding Events (MBEs)

    Freedom from major bleeding events (MBEs), defined as either fatal bleeding, clinically overt bleeding associated with a decrease in haemoglobin of at least 20 g/L in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial or otherwise involves the central nervous system, or bleeding that requires intervention in an operating suite.

    Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period). Up to 97 days.

  2. Steady State Plasma Concentrations of Total Dabigatran at Visit 3

    Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate at visit 3

    Time frame: From the time of randomisation until visit 3

  3. Steady State Plasma Concentrations After at Least 3 Days Following Any Dabigatran Etexilate Dose Adjustment

    Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate after at least 3 days following any dabigatran etexilate dose adjustment

    Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.

  4. Frequency of Dose Adjustment During the Treatment Phase

    Frequency of dose adjustments (i.e. number of patients with dose adjustment), temporary and permanent discontinuation from therapy, and number of patients with laboratory monitoring requirements for dose

    Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period).

  5. Frequency of Patients Switching the Type of Anti-coagulation Therapy Including Dabigatran Etexilate to Standard of Care Treatment and Switching From One Standard of Care Treatment to Another

    Frequency of patients switching the type of anti-coagulation therapy including Dabigatran etexilate (DE) to standard of care (SoC) treatment and switching from one standard of care treatment to another. For DE arm, only the switch from DE to SoC was counted, while for the SoC arm, all switches among SoC treatments were counted.

    Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period).

  6. Freedom From Thrombus Progression at End of Therapy Compared With Baseline

    Freedom from thrombus progression at end of therapy compared with baseline, based on adjudication-confirmed data.

    Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.

  7. All Bleeding Events

    The number of participants with bleeding events includes major bleeding events (MBEs), clinically relevant non-major (CRNM) bleeding, minor bleeding events, any bleeding events, and the numbers of the combined endpoint of major and CRNM bleeding events was presented, based on adjudication-confirmed data.

    Time frame: From first administration of trial medication until last adminstration of trial medication +6 days (residual effect period). Up to 97 days.

  8. All-cause Mortality

    Patients being alive at the end of observational period will be censored for all-cause mortality at the date of patients' last date known to be alive, or the date of data cut-off whichever comes first.

    Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period). Up to 97 days.

  9. All Components of the Primary Efficacy Endpoint

    Patients with VTE-related death occurring between randomisation to Day 84 + 7 days were considered as not meeting the endpoint. The presence of recurrent VTE(s) was examined throughout the trial, and only the date of first occurrence was used for analysis. Assessment of index VTE status (best overall response) was scheduled on Day 84 ± 7 days (Visit 8) for patients who were alive without an early consent withdraw. In the case a Patient discontinued trial medication prematurely due to any reason the index VTE assessment took place at the early end of treatment visit.

    Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.

  10. Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Capsules)

    Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire capsules: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire capsules: How acceptable was the DE treatment for the child? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Patients questionnaire capsules: Was taking the study capsules easy or difficult? The score is 1 (Very easy), 2 (easy), 3 (neither easy nor difficult), 4 (difficult) and 5 (very difficult). Scores refers to the end of treatment.

    Time frame: Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.

  11. Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Pellets)

    Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire pellets: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire pellets: Do you think that spitting occurs? The score is 1 (Never), 2 (sometimes) and 3 (often). Scores refers to the end of treatment.

    Time frame: Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.

  12. Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Oral Liquid Formulation - OLF)

    Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire flavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Investigator questionnaire unflavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire flavoured OLF.: Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Parents questionnaire unflavoured OLF:Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Scores refers to the end of treatment.

    Time frame: Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.

07

Results

Posted Jul 7, 2020

Participant flow

A multi-centre, open-label, randomised, parallel-group, active-controlled, non-inferiority trial of dabigatran etexilate (DE) versus standard of care (SoC) in children from birth to less than 18 years of age.

Participant flow — Overall Study
MilestoneDabigatran EtexilateStandard of Care
Started17790
Treated17690
Completed16885
Not completed95
Withdrew: Adverse event12
Withdrew: Lost to follow-up20
Withdrew: Not treated10
Withdrew: Other reasons32
Withdrew: Non-compliance with the ctp21

Outcome measures

PrimaryComposite Primary Endpoint

The primary endpoint was the combined endpoint of the proportions of patients with: * Complete thrombus resolution * Freedom from recurrent VTE * Freedom from mortality related to VTE. The events outlined in the above combined primary endpoint were assessed by radiologists or other such qualified clinicians using an appropriate method such as ultrasound, echocardiography, venography, or CT scan, based on the location of the thrombus and the test used to perform the baseline assessment. The primary efficacy endpoint contained 3 components. Each component was evaluated separately, and only if the criteria for all 3 components were satisfied, the primary endpoint was considered achieved.

Time frame:
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
Reported as:
Count of participants · Participants
Composite Primary Endpoint
ParticipantsDabigatran EtexilateStandard of Care
Complete thrombus resolution8138
Freedom from recurrent VTE17083
Freedom from mortality related to VTE17789
Composite endpoint met8138
Statistical analysis
  • Dabigatran Etexilate vs Standard of Care · Cochran-Mantel-Haenszel · p = = 0.0001 (p-value for non-inferiority is actually \<0.0001) · Difference in rates: -0.038 · 90% CI -0.141 to 0.066Difference in rates (SOC - DE)
SecondaryFreedom From Major Bleeding Events (MBEs)

Freedom from major bleeding events (MBEs), defined as either fatal bleeding, clinically overt bleeding associated with a decrease in haemoglobin of at least 20 g/L in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial or otherwise involves the central nervous system, or bleeding that requires intervention in an operating suite.

Time frame:
From first administration of trial medication until last administration of trial medication +6 days (residual effect period). Up to 97 days.
Reported as:
Number · Proportion of participants
Freedom From Major Bleeding Events (MBEs)
Proportion of participantsDabigatran EtexilateStandard of Care
Freedom From Major Bleeding Events (MBEs)0.977 (0.948 to 0.990)0.977 (0.929 to 0.993)
Statistical analysis
  • Dabigatran Etexilate vs Standard of Care · Kaplan-Meier estimate · Kaplan-meier estimate: 0.000 · 90% CI -0.032 to 0.032Kaplan-Meier estimate of rate difference.
SecondarySteady State Plasma Concentrations of Total Dabigatran at Visit 3

Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate at visit 3

Time frame:
From the time of randomisation until visit 3
Reported as:
Geometric mean · nanogram per milliliter
Steady State Plasma Concentrations of Total Dabigatran at Visit 3
nanogram per milliliterDabigatran Etexilate
Steady State Plasma Concentrations of Total Dabigatran at Visit 379.8 ± 68.6
SecondarySteady State Plasma Concentrations After at Least 3 Days Following Any Dabigatran Etexilate Dose Adjustment

Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate after at least 3 days following any dabigatran etexilate dose adjustment

Time frame:
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
Reported as:
Geometric mean · nanogram per milliliter
Steady State Plasma Concentrations After at Least 3 Days Following Any Dabigatran Etexilate Dose Adjustment
nanogram per milliliterDabigatran Etexilate
Steady State Plasma Concentrations After at Least 3 Days Following Any Dabigatran Etexilate Dose Adjustment81.7 ± 54.7
SecondaryFrequency of Dose Adjustment During the Treatment Phase

Frequency of dose adjustments (i.e. number of patients with dose adjustment), temporary and permanent discontinuation from therapy, and number of patients with laboratory monitoring requirements for dose

Time frame:
From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
Reported as:
Count of participants · Participants
Frequency of Dose Adjustment During the Treatment Phase
ParticipantsDabigatran EtexilateStandard of Care
With dose adjustment6356
With temporary interruption256
Laboratory monitoring required17582
SecondaryFrequency of Patients Switching the Type of Anti-coagulation Therapy Including Dabigatran Etexilate to Standard of Care Treatment and Switching From One Standard of Care Treatment to Another

Frequency of patients switching the type of anti-coagulation therapy including Dabigatran etexilate (DE) to standard of care (SoC) treatment and switching from one standard of care treatment to another. For DE arm, only the switch from DE to SoC was counted, while for the SoC arm, all switches among SoC treatments were counted.

Time frame:
From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
Reported as:
Count of participants · Participants
Frequency of Patients Switching the Type of Anti-coagulation Therapy Including Dabigatran Etexilate to Standard of Care Treatment and Switching From One Standard of Care Treatment to Another
ParticipantsDabigatran EtexilateStandard of Care
Frequency of Patients Switching the Type of Anti-coagulation Therapy Including Dabigatran Etexilate to Standard of Care Treatment and Switching From One Standard of Care Treatment to Another222
SecondaryFreedom From Thrombus Progression at End of Therapy Compared With Baseline

Freedom from thrombus progression at end of therapy compared with baseline, based on adjudication-confirmed data.

Time frame:
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
Reported as:
Count of participants · Participants
Freedom From Thrombus Progression at End of Therapy Compared With Baseline
ParticipantsDabigatran EtexilateStandard of Care
Freedom From Thrombus Progression at End of Therapy Compared With Baseline14873
SecondaryAll Bleeding Events

The number of participants with bleeding events includes major bleeding events (MBEs), clinically relevant non-major (CRNM) bleeding, minor bleeding events, any bleeding events, and the numbers of the combined endpoint of major and CRNM bleeding events was presented, based on adjudication-confirmed data.

Time frame:
From first administration of trial medication until last adminstration of trial medication +6 days (residual effect period). Up to 97 days.
Reported as:
Count of participants · Participants
All Bleeding Events
ParticipantsDabigatran EtexilateStandard of Care
Any bleeding3822
Major bleeding42
CRNM bleeding21
Minor bleeding3321
Major and CRNM bleeding63
Statistical analysis
  • Dabigatran Etexilate vs Standard of Care · Hazard ratio (hr): 1.145 · 90% CI 0.736 to 1.780
SecondaryAll-cause Mortality

Patients being alive at the end of observational period will be censored for all-cause mortality at the date of patients' last date known to be alive, or the date of data cut-off whichever comes first.

Time frame:
From first administration of trial medication until last administration of trial medication +6 days (residual effect period). Up to 97 days.
Reported as:
Number · Participants
All-cause Mortality
ParticipantsDabigatran EtexilateStandard of Care
All-cause Mortality01
Statistical analysis
  • Dabigatran Etexilate vs Standard of Care · Cox proportional hazard model · p = 0.9976 · Hazard ratio (hr): 69990000 · 90% CI 0.000 to 999999999Upper Limit of the 90% confidence interval was not assessable
SecondaryAll Components of the Primary Efficacy Endpoint

Patients with VTE-related death occurring between randomisation to Day 84 + 7 days were considered as not meeting the endpoint. The presence of recurrent VTE(s) was examined throughout the trial, and only the date of first occurrence was used for analysis. Assessment of index VTE status (best overall response) was scheduled on Day 84 ± 7 days (Visit 8) for patients who were alive without an early consent withdraw. In the case a Patient discontinued trial medication prematurely due to any reason the index VTE assessment took place at the early end of treatment visit.

Time frame:
From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
Reported as:
Count of participants · Participants
All Components of the Primary Efficacy Endpoint
ParticipantsDabigatran EtexilateStandard of Care
Complete thrombus resolution by Day 848138
Recurrent VTE by Day 8477
VTE-related death by Day 8401
SecondaryAssessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Capsules)

Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire capsules: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire capsules: How acceptable was the DE treatment for the child? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Patients questionnaire capsules: Was taking the study capsules easy or difficult? The score is 1 (Very easy), 2 (easy), 3 (neither easy nor difficult), 4 (difficult) and 5 (very difficult). Scores refers to the end of treatment.

Time frame:
Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.
Reported as:
Mean · Score
Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Capsules)
ScoreDabigatran Etexilate
Investigator questionnaire capsules1.0 ± 0.2
Parents questionnaire capsules1.0 ± 0.0
Patient questionnaire capsules1.6 ± 0.9
SecondaryAssessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Pellets)

Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire pellets: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire pellets: Do you think that spitting occurs? The score is 1 (Never), 2 (sometimes) and 3 (often). Scores refers to the end of treatment.

Time frame:
Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.
Reported as:
Mean · Score
Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Pellets)
ScoreDabigatran Etexilate
Investigator questionnaire pellets1.2 ± 0.6
Parents questionnaire pellets1.2 ± 0.5
SecondaryAssessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Oral Liquid Formulation - OLF)

Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire flavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Investigator questionnaire unflavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire flavoured OLF.: Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Parents questionnaire unflavoured OLF:Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Scores refers to the end of treatment.

Time frame:
Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.
Reported as:
Mean · Score
Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Oral Liquid Formulation - OLF)
ScoreDabigatran Etexilate
Investigator questionnaire flavoured OLF1.6 ± 0.8
Investigator questionnaire unflavoured OLF1.2 ± 0.4
Parents questionnaire flavoured OLF1.4 ± 0.5
Parents questionnaire unflavoured OLF1.8 ± 0.4

Adverse events

Collected over For DE patients all AEs recorded between first dabigatran etexilate (DE) intake until 6 days after the last administration of dabigatran etexilate. For patients in standard of care arm, all AEs occurred between the first drug intake of standard of care (SOC) until 6 days after the last administration of any standard of care. The Open-label treatment period with DE or SOC is from vist 2 defined as day 0 up to 84 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate2/176 (1.1%)25/176 (14.2%)59/176 (33.5%)
Standard of Care2/90 (2.2%)18/90 (20%)16/90 (17.8%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventDabigatran EtexilateStandard of Care
Deep vein thrombosisVascular disorders2/1763/90
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1762/90
Febrile neutropeniaBlood and lymphatic system disorders3/1760/90
HaematocheziaGastrointestinal disorders2/1761/90
Sickle cell anaemia with crisisBlood and lymphatic system disorders0/1761/90
Cardiac arrestCardiac disorders0/1761/90
Cardiac failureCardiac disorders0/1761/90
TachycardiaCardiac disorders0/1761/90
PapilloedemaEye disorders0/1761/90
Peritoneal haemorrhageGastrointestinal disorders0/1761/90
Most frequent other events
Most frequent other events
EventDabigatran EtexilateStandard of Care
HeadacheNervous system disorders17/1764/90
VomitingGastrointestinal disorders14/1761/90
NasopharyngitisInfections and infestations11/1767/90
EpistaxisRespiratory, thoracic and mediastinal disorders8/1766/90
PyrexiaGeneral disorders11/1763/90
DyspepsiaGastrointestinal disorders10/1760/90
DiarrhoeaGastrointestinal disorders9/1761/90

Baseline characteristics

The randomised set (RS) included all randomised patients in the treatment groups to which they were randomised, regardless whether they took trial medication

Age, Continuous
Age, Continuous(Years)Dabigatran EtexilateStandard of CareTotal
Mean11.1 ± 6.111.0 ± 6.111.1 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran EtexilateStandard of CareTotal
Female9638134
Male8152133
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dabigatran EtexilateStandard of CareTotal
Hispanic or Latino8311
Not Hispanic or Latino16986255
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dabigatran EtexilateStandard of CareTotal
American Indian or Alaska Native000
Asian10313
Native Hawaiian or Other Pacific Islander000
Black or African American134
White16382245
More than one race202
Unknown or Not Reported123
08

Study locations

65 sites
  • University of California Davis
    Sacramento, California 95817, United States
  • University of Miami
    Miami, Florida 33136, United States
  • St. Joseph's Children's Hospital
    Tampa, Florida 33607, United States
  • Blank Children's Hospital
    Des Moines, Iowa 50309, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Providence Sacred Heart Medical Center and Children's Hospital
    Spokane, Washington 99204, United States
  • Hospital General de Niños Pedro de Elizalde
    Caba, C1270AAN, Argentina
  • Medical University of Innsbruck
    Innsbruck, 6020, Austria
  • AKH - Medical University of Vienna
    Wien, 1090, Austria
  • Brussels - UNIV Saint-Luc
    Bruxelles, 1200, Belgium
  • UNIV UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas
    Campinas, 13059-740, Brazil
  • Faculdade de Ciencias Medicas da UNICAMP
    Campinas, 13083-970, Brazil
  • PenSI - Pesquisa e Ensino em Saude Infantil
    Sao Paulo, 01227-200, Brazil
  • Instituto de Crianca / Hospital das Clínicas-FMUSP
    Sao Paulo, 05403-000, Brazil
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • CHU Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
  • University Hospital Brno
    Brno, 61300, Czechia
  • General Univ.hosp Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • University Hospital Olomouc
    Olomouc, 77900, Czechia
  • University Hospital Ostrava
    Ostrava, 70852, Czechia
  • University Hospital Plzen, Plzen-Lochotin
    Plzen-Lochotin, 304 60, Czechia
  • University Hospital Motol
    Prague, 15006, Czechia
  • Rigshospitalet, København, Børneonkologisk Afsnit 5002
    Copenhagen, 2100, Denmark
  • TaUH, Pediatric Early Phase Trial Unit
    Tampere, 33520, Finland
  • HOP de la Cavale Blanche
    Brest cedex, 29609, France
  • Universitätsklinikum Essen AöR
    Essen, 45147, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • "Aghia Sophia" Children's Hospital
    Athens, 11527, Greece
  • University Debrecen Hospital
    Debrecen, 4032, Hungary
  • Shaare Zedek Medical Center, Jerusalem 91031
    Jerusalem, 9103102, Israel
  • Università degli Studi "La Sapienza"
    Roma, 00161, Italy
  • Ospedale Infantile Regina Margherita
    Torino, 10126, Italy
  • Children Intensive Care Hosp,Anaesthesiology Dept,Vilnius
    Vilnius, 08406, Lithuania
  • Instituto Nacional de Pediatría
    México D.F, 04530, Mexico
  • Hospital Universitario Dr Jose Eleuterio Gonzalez
    Nuevo León, 64460, Mexico
  • Haukeland Universitetssykehus
    Bergen, N-5021, Norway
  • Oslo Universitetssykehus HF, Rikshospitalet
    Oslo, N-0372, Norway
  • Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan
    Kazan, 420138, Russian Federation
  • Science Res.Instit.CV Diseases,Scientific Res.Dept,Kemerovo
    Kemerovo, 650002, Russian Federation
  • Izmilovskaya Child City ClinHosp,Haematological Dept, Moscow
    Moscow, 105077, Russian Federation
  • Child.CityClin.Hos.na.ZA Bashlyaeva MoscowHealth Dep,Cardiol
    Moscow, 125373, Russian Federation
  • St.Petersburg State Pediatric Univ.Ministry of Healthcare RF
    St. Petersburg, 194100, Russian Federation
  • Reg Clin.Hosp.#1,Healthcare Tyumen Region,Cardiovas.Surgery
    Tyument, 625023, Russian Federation
  • Childr.CityClin.Hos#9,pediatric&Neonatal Neurol.Ekaterinburg
    Yekaterinburg, 620134, Russian Federation
  • Hospital Infantil Universitario Niño Jesus
    Madrid, 28009, Spain
  • Sahlgrenska US, Göteborg
    Göteborg, 41345, Sweden
  • Karolinska Univ. sjukhuset
    Solna, 171 65, Sweden
  • Universitäts-Kinderspital
    Zürich, 8032, Switzerland
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Cukurova Universitesi Tip Fakultesi Cocuk Sagligi
    Adana, 1330, Turkey
  • Hacettepe Universitesi Tip Fakultesi
    Ankara, 06100, Turkey
  • Akdeniz Universitesi Tip Fakultesi
    Antalya, 7058, Turkey
  • Istanbul Universitesi Cerrahpasa Tip Fakultesi
    Istanbul, 34098, Turkey
  • Istanbul Saglik Bilimleri Uni. Kanuni Sultan Suleyman EAH
    Istanbul, 34303, Turkey
  • Ege Universitesi Tip Fakultesi Cocuk Hematolojisi Bilim Dali
    Izmir, 35040, Turkey
  • Necmettin Erbakan Universitesi Meram Tip Fakultesi
    Konya, 42080, Turkey
  • Reg.Children Hosp.Dnipropetrovsk
    Dnipropetrovsk, 49100, Ukraine
  • Reg.Children Hosp,Vinnytsia
    Vinnytsya, 21029, Ukraine
09

References and documents

Publications

  • Brandao LR, Tartakovsky I, Albisetti M, Halton J, Bomgaars L, Chalmers E, Luciani M, Saracco P, Felgenhauer J, Lvova O, Simetzberger M, Sun Z, Mitchell LG. Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv. 2022 Nov 22;6(22):5908-5923. doi: 10.1182/bloodadvances.2021005681. PubMed 36150047 ↗
  • Halton J, Brandao LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Sharathkumar A, Svirin P, Gorbatikov K, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Reilly P, Brueckmann M, Albisetti M; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021 Jan;8(1):e22-e33. doi: 10.1016/S2352-3026(20)30368-9. Epub 2020 Dec 5. PubMed 33290737 ↗
  • Albisetti M, Biss B, Bomgaars L, Brandao LR, Brueckmann M, Chalmers E, Gropper S, Harper R, Huang F, Luciani M, Manastirski I, Mitchell LG, Tartakovsky I, Wang B, Halton JML. Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. Res Pract Thromb Haemost. 2018 Mar 25;2(2):347-356. doi: 10.1002/rth2.12086. eCollection 2018 Apr. PubMed 30046738 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Oct 2019, 72 months.

Results were first posted in Jul 2020, 8 months after primary completion.

Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 72 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2013
First posted
Jul 11, 2013
StartActual
Sep 25, 2013
Primary completionActual
Oct 16, 2019
CompletionActual
Nov 14, 2019
Results first posted
Jul 7, 2020
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01895777
Responsible party
Sponsor
First posted
Jul 11, 2013
Start date
Sep 25, 2013
Primary completion
Oct 16, 2019
Completion
Nov 14, 2019
Results posted
Jul 7, 2020
Last update
Jul 7, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion